Repatha's Cardiovascular Benefits Are Driving Labelling Changes

September 2018

You'll get questions about Repatha to reduce risk of CV events.

This PCSK9 inhibitor is now approved for patients with CV disease to reduce the risk of CV events.

This is a case of labelling catching up with the evidence.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Recalls Navigate the Valsartan Recall
Lice Sort Through Head Lice Treatments
Gout Recommend Allopurinol Over Febuxostat for Most Chronic Gout Patients
Cannabinoids Demystify Cannabidiol Oil
Diabetes Expect to Hear About Renal Protection With Flozins and GLP-1 Agonists
Antibiotics More Warnings Will Further Limit Quinolone Use
Eczema Know Where Eucrisa and Dupixent Fit Into Eczema Management
Psoriasis Don't Expect Siliq to Change Practice in the Crowded Psoriasis Market
Diabetes & Endocrinology Use a Stepwise Approach for Treating Hirsutism
Cardiology Repatha's Cardiovascular Benefits Are Driving Labelling Changes
Medication Errors Stay Sharp to Prevent Errors With Vaccines